Annual Low Dose CT (LDCT) screening of patients with a high risk of developing lung cancer has demonstrated a 20% reduction in lung cancer mortality thanks to early stage detection. Early diagnosis more than triples the 5-year survival rate to 56% if the tumor is found localized, but unfortunately only 16% of lung cancers are diagnosed while still localized. Lung cancer screening with low-dose CT (LDCT) scans is leading to a significant increase in the number of patients diagnosed with lung nodules. Over 95% of positive CT scans are false positives (i.e. not cancer).
A positive EarlyCDT-Lung result can help ‘rule-in’ whether pulmonary nodules are malignant.
About Lung Cancer
Each year, lung cancer kills nearly 160,000 Americans— taking more lives than breast, prostate, colon, liver, kidney, and skin cancers combined.(1) When lung cancer is caught early, 54% of patients survive for 5 years or more. But because this disease has no early symptoms, it is usually detected when the cancer has already spread and chances of survival are slim. 85% of lung cancers are diagnosed late-stage.
1. National Cancer Institute SEER Stat Fact Sheets: Lung and Bronchus
EarlyCDT-Lung is an advanced, molecular diagnostic that measures seven autoantibodies in blood that identify elevated risk of lung cancer. EarlyCDT-Lung aids the assessment of malignancy risk in pulmonary nodules. EarlyCDT-Lung can help reduce the number of patients in ‘watchful waiting’ and aid early lung cancer detection, leading to earlier intervention and better patient outcomes